Beta-Endorphin

Beta-endorphin is a 31-amino acid endogenous opioid peptide derived from the precursor protein proopiomelanocortin (POMC) in the anterior pituitary gland and hypothalamic neurons. Discovered in 1976 by Choh Hao Li and David Chung, beta-endorphin is the most potent endogenous opioid peptide, with analgesic activity approximately 18-33 times greater than morphine on a molar basis. It acts primarily through mu-opioid receptors (MOR) in the central nervous system.

Beta-endorphin is co-released with ACTH from corticotroph cells of the anterior pituitary in response to stress, pain, and exercise, as both peptides are cleaved from the same POMC precursor. This coordinated release links the endogenous pain-relief system directly to the stress response axis. In the hypothalamus, beta-endorphin-producing neurons in the arcuate nucleus project widely throughout the brain, including to the periaqueductal gray matter (PAG), a key region for descending pain modulation.

The "runner's high" phenomenon — feelings of euphoria, reduced anxiety, and diminished pain perception during and after vigorous exercise — has been attributed in part to increased beta-endorphin release. While the exact contribution of beta-endorphin to the runner's high remains debated (with endocannabinoids also playing a role), exercise-induced elevation of beta-endorphin levels in plasma and cerebrospinal fluid is well-documented.

Beyond pain modulation, beta-endorphin influences numerous physiological processes including immune function, appetite regulation, and reward pathways. It inhibits substance P release in the spinal cord, providing a direct mechanism for pain signal modulation. In the immune system, beta-endorphin is produced by immune cells and can modulate inflammatory responses. Dysregulation of the endogenous opioid system, including beta-endorphin, has been implicated in conditions ranging from chronic pain to depression, addiction, and eating disorders.